Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jiangbo Pharma Names New CEO
Mr Cao is expected to continue his role as the chairman of the company’s board. Earlier, in April 2008, Mr Jin joined Laiyang Jiangbo Pharmaceuticals, the wholly owned
Mr Cao is expected to continue his role as the chairman of the company’s board. Earlier, in April 2008, Mr Jin joined Laiyang Jiangbo Pharmaceuticals, the wholly owned
ClinTec said that its US operations are into servicing international companies on projects by partnering with US CROs that had no or limited international presence. ClinTec claimed that
According to hematopoietic stem cells (HSC) model, the two progenitor cell types, T and B cells, lose the potential to develop into non-lymphocytes (myeloid cells) once they pass
In the study, Votrient has been shown to effectively slow down the progression of advanced RCC, whilst maintaining quality of life (QoL) as shown by the mean change
Convivia is designed to reduce systemic acetaldehyde exposure and related symptoms in liver enzyme aldehyde dehydrogenase (ALDH2) deficiency, or ethanol intolerance, following alcohol consumption. As per the terms
As per the terms of the agreement, Nuokang is expected to get license to register, market and distribute Dianatal Obstetric Gel in Mainland China, Hong Kong, Macao and
Pharma Omnium has increased its research efforts by acquiring two French biotech firms, Mutabilis and Cellvir in June 2009 and May 2010 respectively. The Mutabilis researchers, who were
Dr Scangos has an experience of nearly 25 years in the biotechnology and pharmaceutical industries. Prior to joining Biogen Idec, he served as president and CEO at Exelixis
Invitrogen, the parent of CellzDirect, is a wholly-owned subsidiary of Life Technologies of Carlsbad, California. The complaint alleges that certain processes and methods performed by CellzDirect associated with
TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia. Threshold Pharma is expected to enroll approximately 165 patients with previously untreated, locally advanced,